COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene (ExCentric)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01124240
Recruitment Status : Unknown
Verified July 2011 by Northern Sydney and Central Coast Area Health Service.
Recruitment status was:  Recruiting
First Posted : May 17, 2010
Last Update Posted : July 26, 2011
Merck KGaA, Darmstadt, Germany
Information provided by:
Northern Sydney and Central Coast Area Health Service

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : November 2012
Estimated Study Completion Date : January 2014